Trinity Capital is recommended as a 'Buy' due to its consistent outperformance against major indices and a strong 11.8% yield. The company maintains a diversified portfolio across technology, equipment financing, and life sciences, supporting steady investment growth and attractive payouts. Management issues shares at a premium to net asset value, preserving capital and enabling sustainable dividends without reducing share value. Risk is managed through 77.6% secured loans, wide geographic exposure, and limited concentration, helping the firm remain resilient even in tough economic conditions.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
Genmab reported strong first-half results driven by DARZALEX sales reaching $8.17 billion, already surpassing half of its $16 billion full-year sales target. If second-half sales remain steady, total sales could hit $16.59 billion, exceeding the high...
POSCO International and LG CNS have launched a pilot project to tokenize live trade receivables from over 80 global subsidiaries on the Injective blockchain. This initiative aims to streamline reconciliation and accelerate cash access by using a shar...
VinFast has formed a strategic partnership with akf-Bank to provide tailored financing solutions for its dealers across Germany, enhancing their ability to finance vehicle inventory and support sales to private and fleet customers. This collaboration...
Crypto analyst Ali Martinez predicts Dogecoin could gain up to 150% if it breaks the key resistance level at $0.081. This breakout could lead the price toward $0.177, the next significant supply zone. Technical indicators like MACD show a buy signal,...
